CBIO Description — Gyre Therapeutics Inc
Catalyst Biosciences, together with its subsidiary, is a biopharmaceutical company focused on development and commercialization of Hydronidone for the treatment of NASH (nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease) in the U.S. Hydronidone is being evaluated for the treatment of liver fibrosis associated with a spectrum of chronic liver diseases. A Phase 1 clinical trial of Hydronidone has been completed in the U.S. and generated pharmacokinetic, safety and tolerability data of single and multiple ascending doses of Hydronidone in U.S. healthy subjects.
|
Free CBIO Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Hold (2.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|